Remove Licensing Remove Life Science Remove Pharma Companies
article thumbnail

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

Before the Covid-19 pandemic, government-led investment and engagement in life sciences was relatively restricted worldwide, with the industry mostly funded via private investment. As a result, multiple vaccines, including Pfizer /BioNTech’s mRNA vaccine, Comirnaty, were licensed for use within a year of development beginning.

article thumbnail

4 Life Sciences Trends for 2023

XTalks

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO

XTalks

Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00

article thumbnail

Veeva Systems Summit, Madrid – pharmaphorum reflects

pharmaphorum

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

article thumbnail

Another mRNA company gets snapped up as Merck buys Exelead

pharmaphorum

The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Outsourcing services are on of the pillars of Merck’s business, delivered via its process solutions unit, part of the group’s life sciences division.

article thumbnail

LSX Inv€$tival Showcase round-up

pharmaphorum

On 14th November, investors and life science & healthcare executives descended on London’s famed Old Billingsgate building to attend LSX’s Inv€$tival Showcase, part of Europe’s biggest dedicated healthcare investment week. Investing in the future of the European life sciences. For Müllenbeck, this is an opportunity.

article thumbnail

Pharma By The Numbers: A Retrospective Look at the Industry and 20 Years of Xtalks History

XTalks

In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the life science industry together through first holding physical events, then soon after, hosting exclusively online events. In that time, we’ve gone from running 25 webinars each year to over 400, working with more than 800 expert speakers each year.